Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2014MedicineOpen Access

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

MWMancai WangLZLing Yi ZhangWHWei Han

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2014) studied this question.

synapsesocial.com/papers/6a918b7dca59a4cbdea16eb2https://doi.org/10.1097/md.0000000000000326
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease2013 · 80 citations
  2. 2Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis2013 · 196 citations
  3. 3Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease2013 · 146 citations
  4. 4Targeting<scp>T</scp>‐cell migration in inflammatory bowel disease2012 · 69 citations
  5. 5Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis2011 · 247 citations